Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lonalidomide as Post-Autologous STem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration

Date Added
November 6th, 2019
PRO Number
Pro00094224
Researcher
Amarendra Neppalli

List of Studies

Keywords
Cancer, Cancer/Myeloma
Summary

This study is for patients that have been diagnosed with multiple myeloma. The investigational drugs in this study are lenalidomide and daratumumab. The purpose of this study is to compare overall survival between the two treatment arms with lenalidomide as the comparator arm and lenalidomide + daratumumab/rHuPH20 as the experimental arm in post-autologous transplant multiple myeloma patients. Participants can expect to be on this study for up to 7 years. After 7 years, participants may be followed by telephone for up to 15 years from the time they started study treatment.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Date Added
August 7th, 2019
PRO Number
Pro00089654
Researcher
Amarendra Neppalli

List of Studies

Keywords
Cancer, Transplant
Summary

This study is for participants that require an allogenic peripheral blood stem cell transplant. The purpose of this study is to compare 2 combinations of drugs to prevent graft-versus-host disease (GVHD), a serious complication of a stem cell transplant. These combinations are either Tacrolimus/methotrexate or Tacrolimus/mycophenolate mofetil/cyclophosphamide. Doctors want to know which combination is better or if they give the same results. The study will help doctors decide which treatment is best at preventing GVHD for future transplant patients. Participants can expect to be in this study for up to 2 years after transplant.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Date Added
July 29th, 2019
PRO Number
Pro00090904
Researcher
Amarendra Neppalli

List of Studies

Keywords
Cancer, Cancer/Myeloma
Summary

This study is for patients that have been diagnosed with smoldering multiple myeloma (SMM). The drugs used in this study are daratumumab, lenalidomide and dexamethasone which are all commercially used drugs. The purpose of this study is to compare overall survival in patients with high-risk smoldering multiple myeloma randomized to daratumumab revlimid-dexamethasone or revlimid-dexamethasone. Participants can expect to be on this study for up to two years and followed by your doctor for up to 15 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu



-- OR --